| The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein LM Lucas, V Dwivedi, JI Senfeld, RL Cullum, CP Mill, JT Piazza, IN Bryant, ... Pharmacological Reviews 74 (1), 18-47, 2022 | 39 | 2022 |
| Development and application of high-throughput screens for the discovery of compounds that disrupt ErbB4 signaling: Candidate cancer therapeutics RL Cullum, LM Lucas, JI Senfeld, JT Piazza, LT Neel, K Whig, L Zhai, ... Plos one 15 (12), e0243901, 2020 | 4 | 2020 |
| Abstract A21: Identification of putative melanoma driver mutations in the ErbB4 receptor tyrosine kinase gene RL Cullum, TM Ghosh, LM Lucas, D Waits, KM Halanych, DJ Riese Cancer Research 80 (19 Supplement), A21-A21, 2020 | | 2020 |
| Abstract A19: Discovery and characterization of selective and nonselective inhibitors of ErbB4 signaling: Putative targeted melanoma therapeutics LM Lucas, RL Cullum, JI Senfeld, LJ Cook, MH Harris, DZ Kaufmann, ... Cancer Research 80 (19 Supplement), A19-A19, 2020 | | 2020 |
| Discovery and characterization of selective and nonselective inhibitors of ErbB4 signaling: Putative targeted melanoma therapeutics. LM Lucas, RL Cullum, JI Senfeld, LJ Cook, MH Harris, DZ Kaufmann, ... CANCER RESEARCH 80 (19), 40-41, 2020 | | 2020 |
| Identification of putative melanoma driver mutations in the ErbB4 receptor tyrosine kinase gene. RL Cullum, TM Ghosh, LM Lucas, D Waits, KM Halanych, DJ Riese CANCER RESEARCH 80 (19), 41-42, 2020 | | 2020 |
| Abstract A159: Characterization of putative ErbB4 antagonists: targeted melanoma drug discovery RL Cullum, LM Lucas, JT Piazza, JI Senfeld, LT Neel, RB Gupta, ... Molecular Cancer Therapeutics 17 (1 Supplement), A159-A159, 2018 | | 2018 |
